Syros Pharmaceuticals Net Worth
Syros Pharmaceuticals Net Worth Breakdown | SYRS |
Syros Pharmaceuticals Net Worth Analysis
Syros Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Syros Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Syros Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Syros Pharmaceuticals' net worth analysis. One common approach is to calculate Syros Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Syros Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Syros Pharmaceuticals' net worth. This approach calculates the present value of Syros Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Syros Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Syros Pharmaceuticals' net worth. This involves comparing Syros Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Syros Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Syros Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Syros Pharmaceuticals' net worth research are outlined below:
| Syros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syros Pharmaceuticals has high historical volatility and very poor performance | |
| Syros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Syros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.94 M. Net Loss for the year was (164.57 M) with loss before overhead, payroll, taxes, and interest of (88.25 M). | |
| Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Syros Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from koreatimes.co.kr: Kia begins mass production of Syros compact SUV in India |
Syros Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Syros Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Syros Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Syros Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syros Pharmaceuticals backward and forwards among themselves. Syros Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syros Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blue Owl Capital Holdings Lp | 2024-09-30 | 515.9 K | Ubs O'connor Llc | 2024-09-30 | 359.3 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 313 K | Blackrock Inc | 2024-09-30 | 261.6 K | Omega Fund Management Llc | 2024-09-30 | 251.3 K | Geode Capital Management, Llc | 2024-09-30 | 204.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 160.4 K | Perceptive Advisors Llc | 2024-09-30 | 116.8 K | Renaissance Technologies Corp | 2024-09-30 | 96.4 K | Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 2.8 M | Siren, L.l.c. | 2024-09-30 | 2.6 M |
Follow Syros Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.89 M.Market Cap |
|
Project Syros Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (0.88) | (0.93) | |
| Return On Assets | (0.88) | (0.92) | |
| Return On Equity | (11.36) | (10.79) |
When accessing Syros Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Syros Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Syros Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Syros Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syros Pharmaceuticals. Check Syros Pharmaceuticals' Beneish M Score to see the likelihood of Syros Pharmaceuticals' management manipulating its earnings.
Evaluate Syros Pharmaceuticals' management efficiency
Syros Pharmaceuticals has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.92 in 2025. Return On Capital Employed is likely to drop to -0.93 in 2025. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 6.6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 21.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.68 | 0.64 | |
| Tangible Book Value Per Share | 0.68 | 0.64 | |
| Enterprise Value Over EBITDA | (1.05) | (1.10) | |
| Price Book Value Ratio | 11.92 | 12.51 | |
| Enterprise Value Multiple | (1.05) | (1.10) | |
| Price Fair Value | 11.92 | 12.51 | |
| Enterprise Value | 128.9 M | 99.6 M |
The strategic initiatives led by Syros Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 20.3058 | Revenue | Quarterly Revenue Growth (0.03) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syros Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Syros Pharmaceuticals time-series forecasting models is one of many Syros Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Syros Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Syros Pharmaceuticals Earnings per Share Projection vs Actual
Syros Pharmaceuticals Corporate Management
| James MD | Founder | Profile | |
| Lisa Roberts | Vice Resources | Profile | |
| JD Esq | Chief Development | Profile | |
| Eric Olson | Chief Scientific Officer | Profile | |
| Jason Haas | Chief Officer | Profile |
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.